Extensive-stage Small Cell Lung Cancer (SCLC)

Oncology·MeSH: Small Cell Lung Carcinoma

Prevalence

6.0 / 100K

Incidence

8.0 / 100K/yr

2 drugs in development·1 company·0 clinical trials

Drug Pipeline by Phase

Compare drugs

Frequently asked questions

How many drugs are in development for Extensive-stage Small Cell Lung Cancer (SCLC)?

BioSniper tracks 2 drugs in development for Extensive-stage Small Cell Lung Cancer (SCLC) across 1 company.

What is the prevalence of Extensive-stage Small Cell Lung Cancer (SCLC)?

The estimated prevalence of Extensive-stage Small Cell Lung Cancer (SCLC) is approximately 6.0 per 100,000 population.

Deep-dive into Extensive-stage Small Cell Lung Cancer (SCLC)

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Extensive-stage Small Cell Lung Cancer (SCLC) — Drugs in Development & Clinical Trials | BioSniper